Research has shown that angiotensin converting enzyme (ACE) inhibitors help manage diabetic nephropathy-related issues. They can also slow the progression of diabetic nephropathy in some people.

Hyperkalemia is a serious, often life threatening complication of diabetes-related kidney disease. This is one of the most common electrolyte imbalances experienced by people with kidney disease, or ...

No therapies currently exist that can halt the progression of chronic kidney disease in children or restore the ability of kidney cells to filter blood. Recently, researchers at the GOFARR Laboratory ...

A new study published in the journal of PLOS One showed that urinary podocalyxin (u-PDX), which increases before overt ...

Diabetic nephropathy is a common complication associated with diabetes that affects a person’s kidneys. Several medications may help slow the progression of kidney damage. Early treatment can prevent ...

No therapies currently exist that can halt the progression of chronic kidney disease in children or restore the ability of kidney cells to filter blood. Recently, researchers at the GOFARR Laboratory ...

Iptacopan (Fabhalta) slowed kidney function decline in adults with immunoglobulin A (IgA) nephropathy, according to final data from the phase III APPLAUSE-IgAN study. The study met its primary ...

Between 20 and 50 percent of individuals with IgA nephropathy will experience kidney failure within two decades of diagnosis, though the timeline varies significantly from person to person. Regular ...

AMSTERDAM, Netherlands — A simple, low-cost 5-day course of dietary inorganic nitrate has shown apparent overwhelming benefit in preventing contrast-induced nephropathy (CIN) and reducing subsequent ...

You can seek early diagnosis to slow or prevent IgA nephropathy from progressing. Make sure you follow treatment plans to control blood pressure and decrease kidney damage. You can also make lifestyle ...

Explore emerging IgA nephropathy therapies—complement and BAFF/APRIL inhibitors, targeted budesonide—and why long‑term safety data still lags. How have the KDIGO thresholds from proteinuria changed ...